SPY302.51-0.46 -0.15%
DIA253.49-0.86 -0.34%
IXIC9,402.33+33.34 0.36%

Xenon Pharmaceuticals Q1 EPS $(0.220) Beats $(0.320) Estimate, Sales $7.078M Beat $4.500M Estimate

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.220) per share which beat the analyst consensus estimate of $(0.320) by 31.25 percent. This is a 47.62 percent increase over losses of $(0.420) per

Benzinga · 05/21/2020 20:02

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.220) per share which beat the analyst consensus estimate of $(0.320) by 31.25 percent. This is a 47.62 percent increase over losses of $(0.420) per share from the same period last year. The company reported quarterly sales of $7.078 million which beat the analyst consensus estimate of $4.500 million by 57.29 percent.